The Cambridge Clostridium difficile Study
Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea
- The study was carried out at Addenbrooke’s Hospital in Cambridge.
- 138 elderly patients requiring antibiotic therapy were divided into two equal groups.
- Group 1 received daily one placebo capsule with their prescribed antibiotics for 20 days.
- Group 2 received daily one capsule of 25 billion Lab4 probiotics in conjunction with their prescribed antibiotics for 20 days.
- The efficacy of Lab4 probiotics in the prevention of CDAD was assessed by recording bowel habit and analysing faecal samples.
- The patient group given Lab4 probiotics experienced a lower incidence of Clostridium difficile diarrhoea compared to the placebo group.
- This effect was due to a reduction in the presence of the Clostridium difficile toxin in the Lab4 probiotic group.
% of patients positive for Clostridium difficile associated diarrhoea
% of patients positive for Clostridium difficile toxin
Supplementation with Lab4 probiotics can reduce the incidence of C. difficile diarrhoea in hospitalised patients.